Abstract
Background aims
Human mesenchymal stromal cells (hMSC) are a promising tool for future clinical application, but their use requires rapid cell expansion in media suitable for clinical use. Therefore, we tested the influence of several culture media on colony formation, population doubling (PD) time, cell cycle and surface marker expression.
Methods
hMSC isolated from human bone marrow (BM) obtained from healthy donors were seeded and expanded in different culture media: α-minimum essential medium (MEM) supplemented with 2.5%, 5%, 10% or 20% fetal bovine serum (FBS), 5% or 10% human cord blood serum (hCBS), 5% or 10% human blood serum from AB adult donors (hABS), or mesenchymal stem cell growth medium (MSCGM™). The number, diameter and total area of the colonies formed and PD time were determined, and the cell cycle and 16 surface markers were analyzed.
Results
Colony-forming efficiency was best in α-MEM/hCBS and α-MEM/hABS, good in MSCGM and worst in α-MEM/FBS. The shortest PD time was achieved in media enriched with human sera or MSCGM, while the time was increased in α-MEM/FBS. The largest proliferating fraction was seen in MSCGM followed by media enriched with human sera; the fraction was smallest in α-MEM/FBS. Staining for CD34, CD45, CD235a and CD271 was negative, while that for CD29, CD44, CD73, CD90, CD105 and human leukocyte antigen (HLA)-A, -B, -C was positive in all media tested. Media with human serum did not adversely affect the differentiation potential of hMSC, and differentiation into osteoblasts was enhanced.
Conclusions
The choice of serum influences hMSC expansion and cell properties; α-MEM supplemented with hABS seems to be a promising candidate for clinical use.
Acknowledgments
We thank Jarmila Kasparova for technical assistance, James Dutt for critical reading of the manuscript and Marie Hladikova for statistical analysis. This study was supported by the grants AV0Z50390703, 1M0538, LC554, 309/08/H079 and the EC FP6 projects RESCUE (LSHB-CT-2005-518233) and ENINET (LSHM-CT-2005-019063).
Disclosure of interest
The authors declare that they have no competing financial interests.